Polar Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Polar Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-175,000	Closed	-$3.07M	–	304
2020 Q2	$3.07M	Sell	175,000 -25,000	-13%	-$426K	0.03%	220
2020 Q1	$2.94M	Hold	200,000	–	–	0.03%	231
2019 Q4	$5.02M	Buy	200,000 +109,618	+121%	+$2.09M	0.04%	235
2019 Q3	$1.36M	Sell	90,382 -9,618	-10%	-$187K	0.01%	259
2019 Q2	$2.5M	Buy	+100,000	New	+$2.48M	0.02%	251

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital's CRNX Position: Q3 2020 in Review

Polar Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2020, closing a stake of 175,000 shares — an estimated $3.07M sold.

Polar Capital first reported a position in CRNX in Q2 2019 and held it in 5 quarters. The position peaked at $5.02M in Q4 2019. 71 funds tracked by Wall St. Rank hold CRNX as of Q3 2020.

Polar Capital reported no remaining Crinetics Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Polar Capital sold 175,000 Crinetics Pharmaceuticals shares in Q3 2020, an estimated $3.07M.
Polar Capital first reported a position in Crinetics Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Polar Capital's Crinetics Pharmaceuticals position peaked at $5.02M in Q4 2019.
71 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.